Mizuho's Katz sees 'fertile' conditions driving robust M&A market into 2026

Mizuho Americas head Michal Katz said dealmaking momentum will persist into 2026 as CEOs pursue scale and private-equity firms divest older assets, with 2025 dominated by megadeals over $10bn that more than doubled year‑over‑year to $1.3 trillion, including an $85bn rail deal, a $40bn data-center sale and a $55bn leveraged buyout of Electronic Arts. Katz expects AI-driven “future-proofing” to spur further mid‑market transactions and broaden sector activity into healthcare—citing Pfizer, Abbott, Thermo Fisher and Novartis—while noting rising shareholder activism and idiosyncratic strains in private credit that are prompting tighter documentation and lender scrutiny.

Analysis

Market structure: The surge in megadeals and a second wave of sub-$10B transactions benefits large strategic acquirers (big-cap tech and healthcare: PFE, NVS) and sellers seeking exits, while mid-market private credit lenders and small-cap incumbents face margin pressure. Expect target equities to rerate +5–15% around deal announcements and acquirers’ IG bonds to widen 50–200bp intra-deal depending on leverage; option implied vols for targets should rise 30–80% near rumors. Cross-asset: higher M&A issuance will lift USD demand for cross-border deals, pressure corporate bond spreads, and raise energy/real estate inputs where data centers and logistics deals dominate capex.

Risk assessment: Tail risks include an antitrust/regulatory block on megadeals (probability ~15–25%), a private-credit contagion if another high-profile default occurs (spreads +200–300bp), or an AI optimism reversal that halts deal flow (weeks–months). Immediate (days) risk is rumor-driven volatility; short-term (1–3 months) is credit-tightening and activist-driven forced sales; long-term (6–24 months) is structural consolidation benefiting scale players. Hidden dependency: activism-driven exits can create supply shocks and fire-sale discounts if multiple sellers coincide with tighter private credit.

Trade implications: Direct plays: overweight healthcare acquirers—establish 2–3% longs in PFE and NVS to capture M&A upside over 3–9 months; hedge with 3–6 month 10–20% OTM put protection. Relative value: pair long PFE (or NVS) vs short EXAS (Exact Sciences) — EXAS faces integration/valuation stress post-deal talk; target 200–400bp relative return in 3–6 months. Options: buy 3–6 month call spreads on PFE/NVS (10%/25% strikes) to limit premium spend while capturing 8–20% equity move; buy 1-year CDX HY protection (small notional 0.25–0.5% of portfolio) if HY spreads widen >150bp.

Contrarian angles: Consensus underestimates the duration of mid-market M&A tailwind—expect 12–18 months of elevated deal flow as companies “future-proof” for AI, not just a one-quarter spike. Conversely, optimism may be overdone on cheap credit: if private-credit documentation scrutiny tightens further, deal volume could fall 20–40% and push mid-cap equities lower. Historical parallels (2014–16 buyout wave) show temporary premium compression post-integration; avoid full carry into 12+ months without realized synergies or regulatory clearance.

Key Decisions for Investors

• Establish a 2–3% long position in PFE via buying 3–6 month 10% OTM call spreads (buy 10% OTM, sell 25% OTM) ahead of likely M&A catalysts; set a tactical stop if PFE falls >15% or if no deal-related news within 90 days.
• Initiate a 2% long in NVS common stock for 3–9 months; implement a buy-write (sell 6–9 month calls ~15% OTM) to collect premium and target 8–12% annualized upside; reduce to half size if NVS bond spreads widen >100bp.
• Open a 1–1.5% short/equity-put position on EXAS (buy 6–12 month 30% OTM puts or short shares) to express downside from integration/valuation risk; cover if EXAS announces concrete strategic buyer or receives +20% price action.
• Allocate 0.25–0.5% of portfolio notional to credit insurance: buy 1-year CDX HY protection or equivalent CDS to hedge a scenario where HY spreads widen >150–200bp; trim hedge if spreads compress below +75bp from current levels.